Legal & General Group
BOLT icon

Legal & General Group’s Bolt Biotherapeutics BOLT Stock Holding History

Legal & General Group’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-92
Closed -$4K – 3458
2022
Q2 		$4K Sell
92
-125
-58% -$4.85K ﹤0.01% 3453
2022
Q1 		$12K Sell
217
-57
-21% -$3.84K ﹤0.01% 3356
2021
Q4 		$27K Buy
274
+57
+26% +$10.8K ﹤0.01% 3182
2021
Q3 		$55K Buy
217
+173
+393% +$48.9K ﹤0.01% 2951
2021
Q2 		$14K Sell
44
-21
-32% -$8.53K ﹤0.01% 3389
2021
Q1 		$42K Buy
+65
New +$42.3K ﹤0.01% 2866

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Legal & General Group's BOLT Position: Q3 2022 in Review

Legal & General Group sold out of Bolt Biotherapeutics (BOLT) in Q3 2022, closing a stake of 92 shares — an estimated $4K sold.

Legal & General Group first reported a position in BOLT in Q1 2021 and held it in 6 quarters. The position peaked at $55K in Q3 2021. 56 funds tracked by Wall St. Rank hold BOLT as of Q3 2022.

  • Legal & General Group reported no remaining Bolt Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Legal & General Group sold 92 Bolt Biotherapeutics shares in Q3 2022, an estimated $4K.
  • Legal & General Group first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 6 quarters.
  • Legal & General Group's Bolt Biotherapeutics position peaked at $55K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q3 2022.

Based on Legal & General Group's 13F filing for Q3 2022, filed 14 Nov 2022.